Akili (NASDAQ:AKLI – Get Rating) had its price target increased by Credit Suisse Group from $4.00 to $4.50 in a research report sent to investors on Tuesday, Marketbeat reports. Credit Suisse Group currently has an outperform rating on the stock.
Other equities research analysts also recently issued reports about the stock. Cowen assumed coverage on shares of Akili in a research note on Tuesday, September 6th. They issued an outperform rating for the company. Lifesci Capital reiterated an outperform rating on shares of Akili in a research note on Tuesday, September 6th. Finally, Cowen initiated coverage on shares of Akili in a research note on Tuesday, September 6th. They set an outperform rating for the company.
Akili Price Performance
Shares of AKLI opened at $1.83 on Tuesday. Akili has a twelve month low of $1.57 and a twelve month high of $37.58. The company has a 50 day moving average price of $2.57.
Institutional Investors Weigh In On Akili
Akili Company Profile
Akili, Inc, a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
- Get a free copy of the StockNews.com research report on Akili (AKLI)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.